NCT02291783View on ClinicalTrials.gov

Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Alzheimer's Disease

Interventions

DRUG

HTL0009936

Single dose

DRUG

HTL0009936 placebo

Placebo single dose

Trial Locations (1)

HA1 3UJ

Parexel Early Phase Clinical Unit, Harrow

All Listed Sponsors

lead

Nxera Pharma UK Limited

INDUSTRY

NCT02291783 - Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment | Biotech Hunter | Biotech Hunter